124 related articles for article (PubMed ID: 36842378)
1. A lung adenocarcinoma with rare epidermal growth factor receptor exon 20 V774M mutation was sensitive to osimertinib: A case report and molecular structural analysis.
Zhuang W; Zhong J; Wang J
Lung Cancer; 2023 Apr; 178():131-133. PubMed ID: 36842378
[No Abstract] [Full Text] [Related]
2. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
3. Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.
Kunimasa K; Nishino K; Kukita Y; Matsumoto S; Kawachi H; Kawamura T; Inoue T; Tamiya M; Honma K; Sugimoto N; Yamasaki T; Imamura F; Goto K; Kumagai T
Cancer Genet; 2021 Aug; 256-257():57-61. PubMed ID: 33901930
[TBL] [Abstract][Full Text] [Related]
4. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.
Chiang CL; Yeh YC; Chou TY; Chiu CH
J Formos Med Assoc; 2020 Sep; 119(9):1439-1441. PubMed ID: 32173232
[No Abstract] [Full Text] [Related]
5. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
Li S; Zhao J; Wang Q
J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
[No Abstract] [Full Text] [Related]
6. Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.
Huang J; Wang Y; Zhai Y; Wang J
Thorac Cancer; 2018 Jun; 9(6):745-749. PubMed ID: 29673089
[TBL] [Abstract][Full Text] [Related]
7. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.
Fang YF; Liu PC
Thorac Cancer; 2021 Dec; 12(24):3429-3432. PubMed ID: 34729927
[TBL] [Abstract][Full Text] [Related]
8. Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.
Grolleau E; Haddad V; Boissière L; Falchero L; Arpin D
J Thorac Oncol; 2019 Jul; 14(7):e151-e153. PubMed ID: 31235042
[No Abstract] [Full Text] [Related]
9. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
[TBL] [Abstract][Full Text] [Related]
10. EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.
Copia Sperandio R; Luiza Teixeira Tostes F; Vidal Campregher P; Ribeiro Paes V; Moura F; Schvartsman G
Lung Cancer; 2022 Apr; 166():94-97. PubMed ID: 35245845
[TBL] [Abstract][Full Text] [Related]
11. Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report.
Nukii Y; Miyamoto A; Mochizuki S; Moriguchi S; Takahashi Y; Ogawa K; Murase K; Hanada S; Uruga H; Takaya H; Morokawa N; Kishi K
BMC Cancer; 2019 Feb; 19(1):186. PubMed ID: 30819142
[TBL] [Abstract][Full Text] [Related]
12. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
[No Abstract] [Full Text] [Related]
13. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
Lee K; Kim D; Yoon S; Lee DH; Kim SW
Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
[TBL] [Abstract][Full Text] [Related]
14. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
[TBL] [Abstract][Full Text] [Related]
15. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
Joo JW; Hong MH; Shim HS
Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
[TBL] [Abstract][Full Text] [Related]
17. Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report.
Zhang YJ; Li H; Zhong R; Chen W; Kou G; Liu G; Cheng Y
Clin Lung Cancer; 2020 Sep; 21(5):e493-e496. PubMed ID: 32418825
[No Abstract] [Full Text] [Related]
18. A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
Liang P; Qi L; Guo T; You X; Cui C
Lung Cancer; 2021 Feb; 152():193-195. PubMed ID: 33388164
[No Abstract] [Full Text] [Related]
19. Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.
Schmid S; Stewart EL; Martins-Filho SN; Cabanero M; Wang A; Bao H; Wu X; Patel D; Chen Z; Law JH; Bradbury PA; Shepherd FA; Leighl N; Tsao MS; Pugh T; Bratman SV; Sacher A; Liu G
Clin Lung Cancer; 2020 Sep; 21(5):e488-e492. PubMed ID: 32389504
[No Abstract] [Full Text] [Related]
20. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]